Darren Hodgson, Executive Director MDT Biomarker Lead, Oncology Translational Medicine at GSK shared a post on LinkedIn:
“On 8th May I said goodbye to friends and colleagues after 20 years at AstraZeneca that seem to have gone by in a flash.
Drug development bestows many ups and downs but it is the great people that I was fortunate to work with that will linger long as happy memories of Alderley Park, Gatehouse Park and the Disc. Heartfelt thanks to all for creating those memories and best of luck going forward.
At the same time I am excited to open a new chapter as Executive Director, MDT Biomarker Lead in Oncology Translational Medicine at GSK. Looking forward to the challenge, meeting new colleagues and contributing to more ups than downs !”
Other articles about GSK on OncoDaily.